Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep;123(3):232-239.
doi: 10.1016/j.anai.2019.07.004. Epub 2019 Jul 8.

A call for cost-effectiveness analysis for biologic therapies in chronic rhinosinusitis with nasal polyps

Christopher D Codispoti  1 , Mahboobeh Mahdavinia  2
Affiliations
Review

A call for cost-effectiveness analysis for biologic therapies in chronic rhinosinusitis with nasal polyps

Christopher D Codispoti et al. Ann Allergy Asthma Immunol. 2019 Sep.

Abstract

Objective: To identify the need for cost-effectiveness analysis of biologic therapies in the treatment of chronic rhinosinusitis (CRS).

Data sources: Clinical trials of monoclonal antibodies (omalizumab, benralizumab, mepolizumab and dupilumab) for nasal polyposis or chronic rhinosinusitis published on PubMed.

Study selections: Clinical trials of biologic therapies in CRS and nasal polyposis.

Results: No cost-effectiveness analyses of biologic therapies in CRS have been performed.

Conclusion: As more clinical trials of biologic therapies for CRS are conducted, there is a need for cost-effectiveness analysis. Future analyses should consider these therapies as part of medical therapeutic options compared with surgery. To increase generalizability, analyses should include samples from allergy and primary care clinics rather than only otolaryngology clinics.

PubMed Disclaimer